AFTD is convening experts from academia and industry in Miami on February 27 for a day-long workshop on TDP-43 biomarkers for FTD and ALS.

Abnormal accumulations of TDP-43, a type of protein, has been linked to both conditions. Researchers are hopeful that TDP-43 could be used as a biomarker to definitively confirm the presence of FTD and/or ALS in the brain while the person affected is still living.

The invited experts will share and discuss their progress on developing biomarkers that can detect TDP-43 in blood or by PET imaging.

AFTD would like to give special thanks to our workshop sponsors, the ALS Association and Target ALS.